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Kidney donation is a meaningful act for the donor,both psychologically and physiologically. As
nephrologists, it is our responsibility to give donors
the best guarantees that this generous act will be as
safe as possible.1 The short-term risk for morbidity or
mortality after kidney donation is very low and
inherent to every surgical procedure.1,2 Numerous
studies have also demonstrated the short-term physi-
ologic consequences of kidney donation in terms of
glomerular ﬁltration rate (GFR), namely a rapid
compensatory hypertrophy of the remaining kidney.
Consequently, in young donors, GFRs soon after
unilateral nephrectomy are 60% to 70% of those
before donation.1,3
The potential major problems with kidney donation
are long-term consequences, such as the risk of
developing chronic kidney disease (CKD), including
end-stage renal disease (ESRD). Epidemiologic data
have recently revived the debate about the safety of
kidney donation by showing an increased relative risk
of ESRD in kidney donors compared with matched
controls.4,5 However, this must be interpreted in light
of the quite small absolute risk.6 Moreover, these
studies, even those including controls, are retrospec-
tive and have been criticized.6,7 Thus, these worri-
some reports are not yet sufﬁcient to dampen living
kidney donation programs, a fact acknowledged by
their authors.5
However, doubt exists, and so the study by Kasiske
et al8 in this issue of AJKD is an important one. The
authors show physiologic data from living kidney
donors over 3 years of follow-up; hence, unlike most
prior data, the new study is more physiologic than
epidemiologic.8 The study has 3 main methodological
strengths. First, the design was prospective and
controlled (with donors paired to controls), whereas
most other studies were either retrospective and/or
without appropriate controls.1,9-12 Second, blood
pressure changes postdonation were assessed by the
gold standard of ambulatory blood pressure moni-
toring. Third, and of prime interest, the authors
measured GFR, by plasma iohexol clearance.
Equations for calculating estimated GFR (eGFR)13,14
have limitations and the precision (at the individual
level) of any equation is probably not sufﬁcient, espe-
cially at high GFRs.13 Also, the ability of eGFR to
evaluate the measured GFR (mGFR) slope over time
remains questionable, particularly at high GFRs.3,15,16
More generally, we still believe that mGFR hasy Dis. 2015;66(1):1-3a role in clinical research in nephrology, particularly
when GFR is considered as a primary end point.13
Reference methods are often described as cumber-
some and costly. However, plasma clearances are far
simpler to do than urinary clearances even if they are
time consuming (at least 4 or 5 hours).17 Moreover, in
Europe, the cost for one GFR measurement is
w$200, which seems acceptable for a reference
method, especially compared with prices of other
“references” in medicine, such as a computed tomo-
graphic scan in pulmonology or an echocardiogram in
cardiology.
The iohexol mGFR data shown by Kasiske et al are
reassuring. The authors observed a signiﬁcant in-
crease in mGFR, with the mean value going from
746 13 mL/min at 6 months to 786 14 mL/min at
3 years.8 The increase in mGFR at 3 years might be
viewed positively, indicating that uninephrectomy
does not accelerate age-related decline in GFR, at
least for the ﬁrst 3 years of follow-up. A more
pessimistic view is that the mGFR increase could
be a detrimental “hyperﬁltration status” because
single-nephron GFR is undoubtedly increased in
the remaining kidney.7 In other words, mGFR of
78 mL/min for one kidney could correspond to mGFR
of 156 mL/min in 2 functioning kidneys.18 In this
scenario, the 3-year follow-up is too limited because
adverse events (ie, decreased GFR) would occur later,
as observed in other hyperﬁltering states such as type
1 diabetes or obesity.10,15,18 In this context, the po-
tential adverse effects of partial ablation of nephron
mass in individuals having a low nephron endowment
at birth, as noted by Brenner and Mackenzie almost
2 decades ago, needs to be taken into consider-
ation,19,20 especially because the Kasiske et al article
has no information on birth weight (and thereby
nephron endowment) of the donors in this study.
Whether this “hyperﬁltration theory” explains the
higher ESRD risk in recent retrospective studies is
debated.4,5 First, hyperﬁltration after kidney donation
could differ pathophysiologically from hyperﬁltration
secondary to diabetes and obesity. Recent physiologic
data have demonstrated that postnephrectomy
hyperﬁltration is attributable to hyperperfusion and1
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glomerular capillary hypertension.7 Second, hyper-
ﬁltration is certainly not the unique pathologic pro-
cess. De novo kidney diseases might also account for
the higher risk of CKD.5,12,21 One study found that
most living kidney donors developing ESRD were
members of the recipient’s family (with common
genetic background) and had immunologically
mediated glomerulonephritis; no case of segmental
glomerulosclerosis was observed.5
The blood pressure and glucose metabolism results
presented by Kasiske are very reassuring. Even with
statistical differences between donors and controls,
the urinary albumin-creatinine ratio (UACR) ﬁndings
are favorable, with a very small, clinically not rele-
vant, increase in UACR after 3 years (from
3.6 [interquartile range (IQR), 2.4-5.8] to 4.2 [IQR,
2.7-7.1] mg/g).8 Although a substantial decline in
UACR after uninephrectomy might have been ex-
pected, the compensatory increase in single-nephron
GFR postuninephrectomy with some changes in
glomerular albumin permeability and/or tubular albu-
min reabsorption might explain the observed slight
increase. Overinterpretation of the results of Kasiske
et al with respect to the impact of uninephrectomy on
albuminuria should be avoided. These ﬁndings also do
not preclude the later development of de novo kidney
disease (such as diabetes).21
More intriguing are the parathyroid hormone
(PTH), phosphorus, homocysteine, and uric acid re-
sults, which signiﬁcantly differ between the 2 groups.8
Regarding higher PTH and lower phosphorus
values in donors, it would have been interesting to
measure calcidiol, calcitriol, and ﬁbroblast growth
factor 23 (FGF-23). FGF-23 measurements would
be of great interest because it has been suggested that
this phosphaturic hormone is the ﬁrst to be abnormally
“hypersecreted” in early CKD stages, including after
kidney donation.22,23 Increased FGF-23 secretion
could lead to increased phosphaturia, inhibition
of 1a-hydroxylase, and a decrease in calcitriol levels,
which would also lower intestinal reabsorption
of both phosphorus and calcium. Calcemia is main-
tained at a normal concentration by an increase in
PTH secretion, which itself promotes phosphaturia
and 1a-hydroxylase activity.23 The data from Kasiske
et al do not conﬁrm or reject this hypothetical sce-
nario. Also, PTH and phosphorus concentrations are in
the reference range for most patients.8 Also reassuring
is that the increase in PTH concentration observed at 6
months is not different after 3-year follow-up, sug-
gesting that a new steady state is reached.24
The increase in donors’ uric acid concentrations (to
5.5 mg/dL after 3 years vs 5.0 mg/dL in controls) is
also of interest. As acknowledged by the authors, the
signiﬁcance of this change on risk of nephrolithiasis,2gout, or CKD progression cannot be determined. We
should also recognize that it remains unclear if uric
acid is a cause or consequence of CKD, an uncertainty
that also applies to the potential increased cardiovas-
cular risk due to hyperhomocysteinemia and uric
acid.25,26 However, as remarked by Kasiske et al, mere
association is not causality. Interventional studies to
decrease homocysteine levels have failed to show
cardiovascular beneﬁt.27 More importantly, unques-
tionable risk factors such as hypertension and hyper-
cholesterolemia are similar during follow-up of the
2 groups. Moreover, most observational retrospective
studies in living kidney donors have not detected
additional cardiovascular risk or mortality.2,11,28-30
Methodological strengths make the study presented
by Kasiske et al of outstanding interest. However,
these reassuring short-term results only apply to
relatively young white nonobese donors. Less opti-
mistic data, even if methodologically less solid, have
recently underlined the potential risk of living dona-
tion in African American (in particular those with risk
alleles at the APOL1 locus)31-33 and obese pa-
tients.11,34 It must be emphasized that only healthy
individuals were included in the Kasiske et al study.
In clinical practice, individuals with minimal pro-
teinuria, not well-controlled hypertension, or marked
obesity are sometimes accepted for living kidney
donation.35 From our point of view, this practice is
very questionable.
There is no doubt that continuing this type of
physiologic study for 5 or 10 years would be of great
value, with the potential of documenting hard end
points such as CKD stage 3b, ESRD, or cardiovas-
cular events. Pending results of such long-term
follow-up studies, a balanced well-informed deci-
sion is possible in most situations involving potential
living kidney donation. We suggest that with caveats,
living kidney donation is reasonably safe. In all
cases, and because prudence and caution is the least
we can offer (primum non nocere), we believe that
careful evaluation (including documentation of birth
weight), education, and long-term medical follow-up
should be kept in mind when considering living
donors.36
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